AbbVie and Gubra A/S, a company specializing in preclinical contract research services and peptide-based drug discovery, have signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales. The transaction closure is subject to regulatory approvals and other customary closing conditions.

“At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists,” said Robert A. Michael, CEO, AbbVie. “Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”

Treating Obesity

GUB014295, currently undergoing a Phase 1 clinical trial, is a promising long-acting amylin analog. It acts as an agonist, specifically activating amylin and calcitonin receptors. Amylin, a satiety hormone, has emerged as a potential therapeutic target for obesity treatment. Its role involves activating signals to the brain that lead to appetite suppression and reduced food intake. Additionally, amylin acts as an inhibitory signal to delay gastric emptying. 

“Building on Gubra’s experience in the discovery of novel peptide-based therapeutics, we look forward to advancing the development of the GUB014295 program,” said Roopal Thakkar, M.D., executive vice president, research & development, chief scientific officer, AbbVie.

“We are excited to partner with AbbVie given its strong capabilities in both the development and commercialization of life-changing medicines,” added Henrik Blou, CEO, Gubra. “This collaboration between Gubra and AbbVie will accelerate the development of GUB014295 and build on the promising data shown in its Phase 1 single ascending dose (SAD) trial. Our team has been extremely impressed with AbbVie and their commitment to bring this important partnership to life. We look forward to working together throughout the development of the GUB014295 program.”

Related Insights

ICON, a CRO, recently conducted a survey of over 100 global industry professionals involved in obesity-related clinical research to gauge opinions of current obesity R&D and its outlook.